
Dr. Abbey Discusses Injectable Retina Treatments on AAO Podcast
On a recent episode of the American Academy of Ophthalmology’s “Experts InSight” podcast, Texas Retina’s Ashkan Abbey, MD, joined Ehsan Rahimy, MD, and host Jay Shridhar, MD, to discuss recent developments in
read more
Dr. Christopher Fuller Won Best in Show at Telluride Retina Film Festival
This past weekend, Texas Retina’s Christopher G. Fuller, MD, presented a video at the Telluride Retina Film Festival, a three-day conference that brings together retina specialists from throughout the Western hemisphere to
read more
Honoring the Life and Legacy of Texas Retina Co-founder Albert Vaiser, MD
It is with great sadness that Texas Retina announces the passing of one of its three founders, Albert Vaiser MD, on Saturday, February 1, 2025, after a brief illness. Dr. Vaiser had celebrated
read more
Dr. Wang Discussed CLARITY Clinical Trial Enrollment at Presentation in Miami
Robert Wang, MD, Texas Retina’s Director of Clinical Research for Plano, recently spoke about the CLARITY clinical trial at a meeting of retina specialists held in Miami, Florida. A global, multi-center Phase
read more
Understanding Your Insurance Coverage in the New Year: How Prior Authorizations Can Impact Retina Care
Health insurance policies and coverage vary greatly. As we start a new year, it is important to understand how your specific plan works and how that can affect your retina care. Referrals
read more
Office Closures for 1/10/2025
Due to the winter weather, the following Texas Retina offices are CLOSED today, January 10, 2025: Dallas North Athens Denton Grapevine Mansfield Sherman Wichita Falls If you have an appointment scheduled that
read more
Winter Weather Closures
Due to the winter weather, the following Texas Retina offices are CLOSED today, January 9, 2025: Dallas North Arlington Athens Frisco Denton Fort Worth Grapevine Plano Sherman Wichita Falls If you have
read more
Dr. Anand Participated in Research on New Gene Therapy Drug for X-linked Retinitis Pigmentosa Published in American Journal of Ophthalmology
The two-year results of the Phase I/II, multi-center HORIZON clinical trial of the new subretinal gene therapy drug AGTC-501 for X-linked retinitis pigmentosa were recently published in the American Journal of Ophthalmology.
read more